O'Donnell MA - Search Results

1

Intravesical treatments of bladder cancer: review.

Shen Z, Shen T, Wientjes MG, O'Donnell MA, Au JL. Shen Z, et al. Pharm Res. 2008 Jul;25(7):1500-10. doi: 10.1007/s11095-008-9566-7. Epub 2008 Mar 28. Pharm Res. 2008. PMID: 18369709 Free PMC article. Review.

2

Interleukin-12. Opportunities for the treatment of bladder cancer.

Clinton SK, Canto E, O'Donnell MA. Clinton SK, et al. Urol Clin North Am. 2000 Feb;27(1):147-55. doi: 10.1016/s0094-0143(05)70242-1. Urol Clin North Am. 2000. PMID: 10696253 Review.

3

Intravenous siRNA Silencing of Survivin Enhances Activity of Mitomycin C in Human Bladder RT4 Xenografts.

Cui M, Au JL, Wientjes MG, O'Donnell MA, Loughlin KR, Lu Z. Cui M, et al. J Urol. 2015 Jul;194(1):230-7. doi: 10.1016/j.juro.2015.02.036. Epub 2015 Feb 11. J Urol. 2015. PMID: 25681288 Free PMC article.

4

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma.

Kamat AM, Bellmunt J, Galsky MD, Konety BR, Lamm DL, Langham D, Lee CT, Milowsky MI, O'Donnell MA, O'Donnell PH, Petrylak DP, Sharma P, Skinner EC, Sonpavde G, Taylor JA 3rd, Abraham P, Rosenberg JE. Kamat AM, et al. J Immunother Cancer. 2017 Aug 15;5(1):68. doi: 10.1186/s40425-017-0271-0. J Immunother Cancer. 2017. PMID: 28807024 Free PMC article.

5

Practical applications of intravesical chemotherapy and immunotherapy in high-risk patients with superficial bladder cancer.

O'Donnell MA. O'Donnell MA. Urol Clin North Am. 2005 May;32(2):121-31. doi: 10.1016/j.ucl.2005.01.003. Urol Clin North Am. 2005. PMID: 15862610 Review.

6

Management of stage T1 tumors of the bladder: International Consensus Panel.

Nieder AM, Brausi M, Lamm D, O'Donnell M, Tomita K, Woo H, Jewett MA. Nieder AM, et al. Urology. 2005 Dec;66(6 Suppl 1):108-25. doi: 10.1016/j.urology.2005.08.066. Urology. 2005. PMID: 16399419

7

The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy.

Joudi FN, Smith BJ, O'Donnell MA, Konety BR. Joudi FN, et al. J Urol. 2006 May;175(5):1634-9; discussion 1639-40. doi: 10.1016/S0022-5347(05)00973-0. J Urol. 2006. PMID: 16600718

8

Safety and efficacy of intravesical bacillus Calmette-Guérin plus interferon α-2b therapy for nonmuscle invasive bladder cancer in patients with prosthetic devices.

Rosevear HM, Lightfoot AJ, Nepple KG, O'Donnell MA. Rosevear HM, et al. J Urol. 2010 Nov;184(5):1920-4. doi: 10.1016/j.juro.2010.06.149. Epub 2010 Sep 17. J Urol. 2010. PMID: 20846678 Clinical Trial.

9

Usefulness of the Spanish Urological Club for Oncological Treatment scoring model to predict nonmuscle invasive bladder cancer recurrence in patients treated with intravesical bacillus Calmette-Guérin plus interferon-α.

Rosevear HM, Lightfoot AJ, Nepple KG, O'Donnell MA. Rosevear HM, et al. J Urol. 2011 Jan;185(1):67-71. doi: 10.1016/j.juro.2010.08.083. Epub 2010 Nov 12. J Urol. 2011. PMID: 21074202

10

Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer.

Kamat AM, Flaig TW, Grossman HB, Konety B, Lamm D, O'Donnell MA, Uchio E, Efstathiou JA, Taylor JA 3rd. Kamat AM, et al. Nat Rev Urol. 2015 Apr;12(4):225-35. doi: 10.1038/nrurol.2015.58. Epub 2015 Mar 24. Nat Rev Urol. 2015. PMID: 25800393 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

225 results

Search Page